S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967792.43327.c1 |
| _version_ | 1827332406661611520 |
|---|---|
| author | Nausheen Ahmed Swetha Kambhampati Mehdi Hamadani Natalie Grover Mazyar Shadman Frederick Locke James Gerson Matthew J. Frank L. Elizabeth Budde Michael Wang Zhen-Huan Hu Ana Nunes David Dalton Ioana Kloos Daniel Lee Hairong Xu Marcelo Pasquini Alex F. Herrera |
| author_facet | Nausheen Ahmed Swetha Kambhampati Mehdi Hamadani Natalie Grover Mazyar Shadman Frederick Locke James Gerson Matthew J. Frank L. Elizabeth Budde Michael Wang Zhen-Huan Hu Ana Nunes David Dalton Ioana Kloos Daniel Lee Hairong Xu Marcelo Pasquini Alex F. Herrera |
| author_sort | Nausheen Ahmed |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:59:25Z |
| format | Article |
| id | doaj.art-d985d6a9077240fe831b6d80cdd69b0d |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:59:25Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-d985d6a9077240fe831b6d80cdd69b0d2024-03-03T03:25:46ZengWileyHemaSphere2572-92412023-08-017e43327c110.1097/01.HS9.0000967792.43327.c1202308003-00122S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENTNausheen Ahmed0Swetha Kambhampati1Mehdi Hamadani2Natalie Grover3Mazyar Shadman4Frederick Locke5James Gerson6Matthew J. Frank7L. Elizabeth Budde8Michael Wang9Zhen-Huan Hu10Ana Nunes11David Dalton12Ioana Kloos13Daniel Lee14Hairong Xu15Marcelo Pasquini16Alex F. Herrera171 The University of Kansas Medical Center, Westwood, United States2 City of Hope National Medical Center, Duarte, United States3 Center for International Blood and Marrow Transplant Research, Milwaukee, United States4 University of North Carolina, Chapel Hill, United States5 Fred Hutchinson Cancer Center, Seattle, United States6 Moffitt Cancer Center, Tampa, United States7 University of Vermont Medical Center, Burlington, United States8 Stanford University, Stanford, United States2 City of Hope National Medical Center, Duarte, United States9 University of Texas MD Anderson Cancer Center, Houston, United States10 Kite, a Gilead Company, Santa Monica, United States10 Kite, a Gilead Company, Santa Monica, United States10 Kite, a Gilead Company, Santa Monica, United States10 Kite, a Gilead Company, Santa Monica, United States10 Kite, a Gilead Company, Santa Monica, United States10 Kite, a Gilead Company, Santa Monica, United States3 Center for International Blood and Marrow Transplant Research, Milwaukee, United States2 City of Hope National Medical Center, Duarte, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000967792.43327.c1 |
| spellingShingle | Nausheen Ahmed Swetha Kambhampati Mehdi Hamadani Natalie Grover Mazyar Shadman Frederick Locke James Gerson Matthew J. Frank L. Elizabeth Budde Michael Wang Zhen-Huan Hu Ana Nunes David Dalton Ioana Kloos Daniel Lee Hairong Xu Marcelo Pasquini Alex F. Herrera S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT HemaSphere |
| title | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_full | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_fullStr | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_full_unstemmed | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_short | S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT |
| title_sort | s220 real world outcomes of brexucabtagene autoleucel brexu cel for relapsed or refractory mantle cell lymphoma a cibmtr subgroup analysis by prior treatment |
| url | http://journals.lww.com/10.1097/01.HS9.0000967792.43327.c1 |
| work_keys_str_mv | AT nausheenahmed s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT swethakambhampati s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT mehdihamadani s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT nataliegrover s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT mazyarshadman s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT fredericklocke s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT jamesgerson s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT matthewjfrank s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT lelizabethbudde s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT michaelwang s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT zhenhuanhu s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT ananunes s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT daviddalton s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT ioanakloos s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT daniellee s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT hairongxu s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT marcelopasquini s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment AT alexfherrera s220realworldoutcomesofbrexucabtageneautoleucelbrexucelforrelapsedorrefractorymantlecelllymphomaacibmtrsubgroupanalysisbypriortreatment |